In January-September 2011, the company posted net profit of RON24.85 million.
Antibiotice reported sales of RON215.1 million (EUR48.5 million) in the first nine months, from RON201.2 million in the year-ago period.
Overall revenue rose 6% on the year to RON229.1 million, while total costs increased at a similar pace to RON198.7 million, according to the company’s preliminary results.
Antibiotice is the second-largest nystatin maker in the world, with a 25% market share, according to company information.
The company’s majority holder is Romania’s Health Ministry, with a 53% stake, while investment fund SIF Oltenia (SIF5.RO) holds a 10% stake.
At around 10:00 am Thursday, Antibiotice traded flat at RON0.3787 a share in Bucharest. (EUR1=RON4.5388)